宜明昂科-B(01541)今日盘中股价大幅上涨11.52%，引起了市场的高度关注。
消息面上，公司近期的研发进展与管线拓展是推动股价上涨的主要因素。公司此前宣布重新收回了自主研发的两款新药IMM2510及IMM27M的全球开发及商业化权利，这为公司未来与更强大的跨国药企达成新的全球授权合作提供了发展空间。此外，公司已获得中国国家药品监督管理局批准其新药IMM0306S（皮下制剂）治疗系统性红斑狼疮(SLE)的新药临床试验申请，这标志着公司的产品线正从肿瘤治疗领域向高增长的自身免疫疾病领域扩展。
有市场分析报告指出，公司作为一家以科研为导向的生物技术公司，拥有丰富的创新候选药物管线，上述进展增强了市场对其长期发展潜力的信心，并给出了积极的目标价评估。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.